secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001628280-25-048557
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints John Harlow as Chief Commercial Officer effective Nov 17, 2025
--------------------------------------------------------------------------------

- John Harlow appointed CCO; base salary $535,000, target bonus 45%, sign-on bonus $35,000.
- Equity grants: option for 380,000 shares and 424,536 RSUs, vesting over four years.
- Harlow previously CCO at Melinta Therapeutics, where revenue nearly doubled (~85% growth from 2020 to 2024).
- He reports to CEO Sheldon Koenig and joins Esperion's Executive Leadership Team.
- Harlow brings over 20 years of pharma commercial leadership from Melinta, Baudax Bio, Endo, Pfizer, and Novartis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025048557/0001628280-25-048557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025048557/espr-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-048557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer